Lymphoma
FDA approves Zynlonta for relapsed or refractory diffuse large B-cell lymphoma
The FDA granted accelerated approval to loncastuximab tesirine-lpyl for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.
Lenzilumab before CAR-T induces high response rates without severe toxicities
A combination of lenzilumab and axicabtagene ciloleucel induced an 83% overall response rate among patients with advanced diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.
Certain patient groups may receive less intensive treatment for mantle cell lymphoma
Patients with mantle cell lymphoma who were unmarried, had less education or had more comorbidities appeared less likely to undergo autologous hematopoietic stem cell transplantation, according to a study published in Blood Advances.
Risk-adapted therapies reduce long-term toxicity in pediatric Hodgkin lymphoma
The use of risk-adapted therapies for pediatric Hodgkin lymphoma has significantly reduced the incidence of serious long-term health problems among survivors, according to a study published in Journal of Clinical Oncology.
Product composition, immune biomarkers linked to CAR-T efficacy
Product attributes appeared associated with more potent and durable responses to axicabtagene ciloleucel among patients with follicular lymphoma, according to an analysis of the ZUMA-5 trial.
Bispecific CAR-T shows early efficacy, ‘exceptional safety’ in advanced B-cell lymphoma
Four of five patients with relapsed or refractory B-cell lymphoma demonstrated complete response to an investigational anti-CD19/CD20 chimeric antigen receptor T-cell therapy, according to early data from a phase 1 trial.
Copanlisib-rituximab combination extends PFS in relapsed indolent non-Hodgkin lymphoma
The addition of copanlisib to rituximab increased response rates and significantly extended PFS among patients with relapsed indolent non-Hodgkin lymphoma, according to study results.
ASH awards support resumption of hematologic research paused by pandemic
ASH awarded funding to 19 early-career investigators to support resumption of research paused due to the COVID-19 pandemic.
Higher disease burden leads to poorer CAR-T outcomes in large B-cell lymphoma
Immune dysregulation resulting from high tumor burden appeared associated with poor chimeric antigen receptor T-cell expansion and resistance among patients with diffuse large B-cell lymphoma, according to study results published in Blood.
FDA approves Yescarta for advanced follicular lymphoma
The FDA granted accelerated approval to axicabtagene ciloleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release from the agent’s manufacturer.